Senti Bio Issues $10M in Highly Dilutive Convertible Notes to Celadon Partners
SNTI sits 29% above its 52-week low of $0.77.
Summary
Senti Biosciences issued $10.0 million in highly dilutive Senior Secured Convertible Notes to Celadon Partners, finalizing a tranche of a previously announced financing with unfavorable terms and increasing Celadon's control.
Key Events · Financing and Capital Events · SNTI
-
Issuance of $10.0 Million Convertible Notes
Senti Holdings, a wholly-owned subsidiary, issued $10.0 million in Senior Secured Convertible Notes to Celadon Partners SPV 24 on May 20, 2026. This transaction executes a portion of the previously announced $40.0 million financing.
-
Highly Dilutive and Unfavorable Terms
The notes are convertible at $0.6261 per share, representing a deep discount to the current stock price of $0.9922. They also include a 200% redemption price upon maturity or event of default and a 12% default interest rate.
-
Increased Investor Control and Restrictive Covenants
The financing includes negative covenants that restrict the company's ability to incur additional debt, create liens, or change its business without the consent of 'Required Holders,' which includes Celadon, indicating significant investor control.
-
Potential Future Merger and CVR
The filing mentions a potential future transaction where an entity affiliated with Celadon would merge into Senti Holdings, and existing stockholders would receive a contingent value right (CVR) tied to SENTI-202 milestones, signaling a major corporate restructuring.
Analysis · SNTI · Life Sciences
Senti Biosciences has issued $10.0 million in Senior Secured Convertible Notes to Celadon Partners, a significant portion of its market capitalization. This transaction finalizes a tranche of the previously announced $40.0 million financing. The notes carry highly unfavorable terms for existing shareholders, including a conversion price of $0.6261 (a substantial discount to the current stock price of $0.9922), a 200% redemption price upon maturity or default, and a 12% default interest rate. These terms, coupled with negative covenants restricting company actions, indicate the company's distressed financial position and the high cost of securing capital, further increasing Celadon's control and potential for significant dilution. The filing also hints at a potential future merger with Celadon and a contingent value right for existing stockholders, which would be a major corporate restructuring.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 43.9% of the 999 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNTI was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.9M. The 52-week trading range was $0.77 to $3.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.